Drug development and Alzheimer disease.
Roses
Allen D
AD
GlaxoSmithKline Research and Development, Genetics Research, Neurology Centre for Excellence in Drug Discovery, Research Triangle Park, NC 27709, USA. Allen.D.Roses@gsk.com
Pangalos
Menelas N
MN
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000818:Animals; D001057:Apolipoproteins E / Q000378:metabolism; D001284:Atrophy; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015195:Drug Design; D004345:Drug Industry; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D051379:Mice; D018345:Mice, Knockout; D008967:Molecular Biology / Q000379:methods
D001057:Apolipoproteins E; D002800:Cholinesterase Inhibitors; D016861:Cyclooxygenase Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors